Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy

Abstract

A substantial number of individuals with type 2 diabetes mellitus (T2DM) demonstrate a predominance of small dense low-density lipoprotein (sdLDL), which is associated with an increased risk of cardiovascular disease (CVD). In some cases, sdLDL persists after treatment with a statin to reduce levels of LDL. The effect of the addition of a thiazolidinedione, rosiglitazone (RSG) (4 mg/day or 8 mg/day) to statin therapy on LDL phenotype and C reactive protein (CRP) levels was investigated in a 12-week, placebo-controlled study of 72 T2DM patients who were well controlled and on a statin, but who had persistently predominant sdLDL.

Addition of RSG 8 mg to statin therapy significantly increased LDL buoyancy (relative flotation +0.014, p=0.003) and LDL particle size (+4.2Å, p=0.001) from baseline and relative to the change with placebo (+0.014 and +3.8Å; p=0.03 and p=0.04, respectively), and was associated with a non-significant decrease in sdLDL. RSG 8 mg moderately, but significantly, increased total cholesterol (by 12.2%, p=0.004), LDL-cholesterol (11.2%, p=0.02) and intermediate-density lipoprotein (IDL)-cholesterol from baseline but did not increase total or LDL apolipoprotein B. RSG 4 mg and 8 mg significantly reduced CRP compared with placebo (-44.9% and-48.0%; p=0.008 and p=0.004, respectively), and significantly reduced insulin resistance and fasting plasma glucose from baseline.

Addition of RSG to statin therapy may further reduce cardiovascular risk by improving the LDL phenotype, as well as reducing insulin resistance and CRP levels. However, the increase in IDL may be proatherogenic and must be considered when assessing the benefits of rosiglitazone.

Keywords

C-reactive protein rosiglitazone small dense low-density lipoprotein phenotype statin thiazolidinediones type 2 diabetes mellitus.

References

1. Haffner SM , Lehto S , Ronnemaa T , Pyorala K , Laakso M Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229–34.

2. Selby JV , Austin MA , Newman B. et al. LDL subclass phenotypes and the insulin resistance syndrome in women. Circulation 1993;88:381–7.

3. Feingold KR , Grunfeld C , Pang M , Doerrler W , Krauss RM LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb 1992;12:1496–502.

4. Austin MA , Mykkanen L , Kuusisto J. et al. Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women. Circulation 1995;92:1770–8.

5. St Pierre AC , Cantin B , Dagenais GR. et al. Low-density lipoprotein sub-fractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005;25:553–9.

6. Sacks FM , Campos H Clinical review 163: Cardiovascular endocrinology: Low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocrinol Metab 2003;88:4525–32.

7. Zambon A , Hokanson JE , Brown BG , Brunzell JD Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 1999;99:1959–64.

8. Zwaka TP , Hombach V , Torzewski J C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001;103:1194–7.

9. Gardner CD , Fortmann SP , Krauss RM Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996;276:875–81.

10.

10. Tornvall P , Karpe F , Carlson LA , Hamsten A Relationships of low density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infarction. Atherosclerosis 1991;90:67–80.

11.

11. Berneis K , Jeanneret C , Muser J , Felix B , Miserez AR Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes. Metabolism 2005;54:227–34.

12.

12. Lee YH , Pratley RE The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep 2005;5:70–5.

13.

13. St Pierre AC , Bergeron J , Pirro M. et al. Effect of plasma C-reactive protein levels in modulating the risk of coronary heart disease associated with small, dense, low-density lipoproteins in men (The Quebec Cardiovascular Study). Am J Cardiol 2003;91:555–8.

14.

14. Pyorala K , Pedersen TR , Kjekshus J , Faergeman O , Olsson AG , Thorgeirsson G Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614–20.

15.

15. Nissen SE , Tuzcu EM , Schoenhagen P et al Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29–38.

16.

16. Collins R , Armitage J , Parish S , Sleight P , Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005–16.

17.

17. Colhoun HM , Betteridge DJ , Durrington PN et al Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685–96.

18.

18. van Tits LJ , Smilde TJ , van Wissen S , de Graaf J , Kastelein JJ , Stalenhoef AF. Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia. J Investig Med 2004;52:177–84.

19.

19. Sirtori CR , Calabresi L , Pisciotta L et al Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin. Nutr Metab Cardiovasc Dis 2005;15:47–55.

20.

20. Freed MI , Ratner R , Marcovina SM et al Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 2002;90:947–52.

21.

21. Fay WP. Plasminogen activator inhibitor 1, fibrin, and the vascular response to injury. Trends Cardiovasc Med 2004;14:196–202.

22.

22. Murdoch SJ , Carr MC , Kennedy H , Brunzell JD , Albers JJ. Selective and independent associations of phospholipid transfer protein and hepatic lipase with the LDL subfraction distribution. J Lipid Res 2002;43:1256–63.

23.

23. Capell WH , Zambon A , Austin MA , Brunzell JD , Hokanson JE. Compositional differences of LDL particles in normal subjects with LDL subclass phenotype A and LDL subclass phenotype B. Arterioscler Thromb Vasc Biol 1996;16:1040–6.

24.

24. Wallace TM , Levy JC , Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487–95.

25.

25. Rosenson RS , Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998;279:1643–50.

26.

26. Freed MI , Fuell D , Menci L , Heise M , Goldstein B. Effect of combination therapy with rosiglitazone and glibenclamide on PAI-1 antigen, PAI-1 activity and tPA in patients with type 2 diabetes. Diabetologia 2000;43:A267.

27.

27. Sakabe K , Fukuda N , Wakayama K , Nada T , Shinohara H , Tamura Y. Lipid-altering changes and pleiotropic effects of atorvastatin in patients with hypercholesterolemia. Am J Cardiol 2004;94:497–500.

28.

28. Dormandy JA , Charbonnel B , Eckland D et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279–89..